NSC13728 inhibited the growth of the MCF7-35IM breast cancer cell line that carries an inducible Myc transgene, and when used in combination with the estrogen antagonist ICI 182,780 that inhibits endogenous Myc expression, an additive reduction was observed. This evidence concerns the gene MYC and breast cancer.